PARTNERSHIPS AND SUPPORT

Do you want to link to this Amgen Site outside the UK and leave Amgen.co.uk?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Please specify your location:

Do you want to link to this External Site and leave Amgen.co.uk?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Collaborative Working initiatives, including Joint Working

At Amgen, we are proud to partner with the NHS and other organisations and are committed to improving patient care through our collaborative working initiatives.

Collaborative working refers to the partnerships formed between pharmaceutical companies and other organisations to deliver initiatives that enhance patient care, are for the benefit of patients, or alternatively benefits the NHS and, as a minimum, maintains patient care. Joint working is a subtype of company collaboration that is specifically patient-centred and designed to always benefit patients.

Full details of our ongoing collaborative working and joint working projects are listed below.

Click here to access the 2021 Amgen UK and Ireland Collaborative Working and Joint Working transfers of value

Click here to access the 2020 Amgen UK and Ireland Collaborative Working and Joint Working transfers of value

Joint Working Initiatives


Title NEXT GEN POPULATION HEALTH IN NHS WALES.
Organisations Involved

Amgen

Hywel Dda University Health Board

Swansea University

Joint Working Project Description

This collaborative working project seeks to bring together stakeholders from NHS Wales and Academia to develop a population health approach for population risk prediction and high intensity intervention in a controlled health system, with a key focus on targeting better outcomes.

The overall aims of the Project are to demonstrate improved outcomes as a result of a comprehensive approach to risk prediction and prevention by:

  • Utilising data analytics to test, validate & improve identification of high-risk patient cohorts e.g. patients at high risk of developing CVD, patients at high risk of CVD with unaddressed risk factors, and those with established CVD not meeting guideline targets for CVD risk management
  • Evaluating different service models for delivering a specific high risk CVD clinic. Using clinical outcomes, patient reported outcomes, Value Based Healthcare Analysis and Health Economic Impact Assessment the project aims to evaluate and ensure the most effective model is sustained across NHS Wales and rolled out across other geographies
Expected Outcomes Benefits to Patients
  • Improved identification of patients with and at high risk of atherosclerotic cardiovascular disease and improved treatment of lipids and other major CVD risk factors via developed service models
  • Improved patient understanding of how lipids and other CVD risk factors contribute to their risk of heart attack and stroke, as well as the rationale for and nature of treatments used to address their risk through shared decision-making
  • Improved patient engagement and empowerment to self-manage
  • Medicines and lifestyle adherence issues identified and addressed early

Benefits to NHS

The Project aligns with the ambition set out in Welsh Government and NHS Wales ‘Quality Statement for Heart Conditions’¹, that the quality attributes of services for people with heart conditions in Wales should be:

  • Effective e.g., Nationally optimised evidence-based pathways for people with heart conditions to be comprehensive and fully embedded in local service delivery.
  • Efficient e.g., Detection, diagnosis, and effective management of high-risk conditions such as high blood pressure, raised cholesterol and atrial fibrillation. Utilising a national approach to informatics systems will enable greater integration of care and provide relevant, high quality, standardised data to drive service improvement.
  • Person centred e.g.Collaborative approach to person-centred care supported by a common approach to diagnosis, treatment and care provided by a multi-disciplinary care team within the community as appropriate.
  • Efficiency savings through service transformation to maximise outcomes, utilising new technologies and models of care.
  • Local reduction in avoidable CVD events.
  • Supporting post-COVID recovery adoptions of new models of care.

Benefits for Amgen

  • The Project aims to increase the identification of sub optimally treated patients at a high risk of a CVD event. Patient management could involve cholesterol lowering medicines which may include an Amgen medicine for suitable patients in line with NICE TA394 and or local / national guidelines
  • Demonstrates collaborative working with the NHS to the benefit of patients and identifies scalable solutions. These may be promoted in other regions, thus raising the reputation of the Company as a partner to work with.Disciplined experimentation to inform future approaches to collaboration and system value (health systems responding to innovative access solutions)

1. The Quality Statement for Heart Conditions: https://gov.wales/quality-statement-heart-conditions-html.

 

GB-NPS-0622-00006 June 2022


 


Title IMPROVING THE IDENTIFICATION AND TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH) AND THE SECONDARY PREVENTION OF PATIENTS WITH HIGH RISK CARDIOVASCULAR DISEASE IN PRIMARY CARE.
Organisations Involved Academic Health Science Network for the North East and North Cumbria (AHSN-NENC) and Amgen Ltd in collaboration with Clinical Commissioning Groups, GP Practices and CDRC (Clinical Digital Resource Collaborative)
Joint Working Project Description

The overall aims of this project are to:

  • Identify patients at high risk of Familial Hypercholesterolemia (FH), evaluate medications, educate and treat patients with the sole aim of reducing excess coronary heart disease risk and premature mortality associated with Familial Hypercholesterolemia (FH).
  • Increase the utilisation of the genetic screening programme across the AHSN footprint through better patient identification.
  • Identify patients at high risk of CVD (>10% 10 year CV risk) and ensure appropriate treatment and management.
  • Improve the patient experience by providing more specialist care within primary care and ensure better utilisation and more appropriate referrals to the specialist service base with the NHS Trust.
  • To continue to refine and develop the FH service model to be adopted both regionally and nationally.
Expected Outcomes

The expected outcomes from this project are as follows:

  • A written document to inform the treatment of Familial Hypercholesterolemia (FH) patients in primary care including information on implementing patient identification using a Familial Hypercholesterolemia (FH) patient identification tool and clinical review at a practice level.
  • A toolkit to include training materials on Familial Hypercholesterolemia (FH) and its treatment for healthcare professionals in primary care and the use of the Familial Hypercholesterolemia (FH) patient identification tool.
  • Implementation of NICE CG71 and the NHS long term plan.

The project incorporates the principles of improved patient education, medicines optimisation and treatment close to home.

GB-REP-0520-00016 May 2020


 


Title Non-Small Cell Lung Cancer (NSCLC) Tissue Pathway Improvement Project.
Organisations Involved Amgen Limited and Manchester University NHS Foundation Trust on behalf of North West Genomics Laboratory Hub (GLH)
Joint Working Project Description

This collaborative working project seeks to bring together a cross functional team from the Genomics Laboratory Hub who in collaboration with Amgen will design and implement a ‘service optimisation project’. 

The primary aim of this twelve month project is to support the optimisation of clinical pathways and outcomes, improving and standardising access and turnaround times within the NSCLC Tissue pathway. 

In addition, this project will also inform and support the delivery of improvements in the National Optimal Lung Cancer Pathway. 

Expected Outcomes

The core outputs and outcomes of the of the project are as follows:

Outputs

  • The delivery of a detailed pathology pathway map for non-small cell lung cancer
  • A detailed report identifying the key barriers and delays within the local non-small cell lung cancer pathology pathway and/or across the local network
  • The development of Optimal Tissue Management guidelines and standard operating policy to support the effective delivery of the non-small cell lung cancer tissue pathway
  • The development of a local ‘case for change’ which supports the continued improvement/ adoption and uptake of genomics testing and informs the local service model
Pathway Outcomes
  • An increased number of lung cancer samples are sent to the GLH vs baseline
  • An improvement in the turnaround time (TAT) from the point of tumour sampling to genomic result v’s baseline
  • An increase and/or standardisation of the quality/type of samples sent for genomic analysis, resulting in the increased success rate of next generation sequencing (NGS) panel and single genome test results
 
Local system outcomes
  • There is an increased level of education and awareness of local clinical teams, who are better able to engage with the processes supporting genomic analysis of non-small cell lung cancer

GB-NPS-1221-00005 December 2021


 


Title Non-Small Cell Lung Cancer (NSCLC) Tissue Pathway Improvement Project.
Organisations Involved Amgen Limited and Royal Devon & Exeter NHS Foundation Trust on behalf of NHS South West Genomic Medicine Service Alliance
Joint Working Project Description

This collaborative working project seeks to bring together a cross functional team from the Genomics Laboratory Hub (GLH) who in collaboration with Amgen will design and implement a ‘service optimisation project’.

The primary aim of this twelve month project is to support the optimisation of clinical pathways and outcomes, improving and standardising access and turnaround times within the NSCLC Tissue pathway. 

In addition, this project will also inform and support the delivery of improvements in the National Optimal Lung Cancer Pathway. 

Expected Outcomes

The core outputs and outcomes of the of the project are as follows:

Outputs

  • The delivery of a detailed pathology pathway map for non-small cell lung cancer
  • A detailed report identifying the key barriers and delays within the local non-small cell lung cancer pathology pathway and/or across the local network
  • The development of Optimal Tissue Management guidelines and standard operating policy to support the effective delivery of the non-small cell lung cancer tissue pathway
  • The development of a local ‘case for change’ which supports the continued improvement/ adoption and uptake of genomics testing and informs the local service model
Pathway Outcomes
  • An increased number of lung cancer samples are sent to the GLH vs baseline
  • An improvement in the turnaround time (TAT) from the point of tumour sampling to genomic result v’s baseline
  • An increase and/or standardisation of the quality/type of samples sent for genomic analysis, resulting in the increased success rate of next generation sequencing (NGS) panel and single genome test results
Local system outcomes
  • There is an increased level of education and awareness of local clinical teams, who are better able to engage with the processes supporting genomic analysis of non-small cell lung cancer

GB-NPS-1221-00006 December 2021


 


Title Predict and Prevent - Transforming the Lipid Pathway in South East London to Improve Patient Outcomes.
Organisations Involved South East London CCG, Guys & St Thomas’ NHS Foundation Trust, King’s College Hospital NHS Foundation Trust.
Joint Working Project Description

This project will assist in the delivery of the CVD ambitions relating to cholesterol outlined by NHS England / PH England in response to the NHS Long-Term Plan.

The primary aim of the project will be to reengineer the local lipid pathway to ensure all patients requiring lipid management are seen by the right person, in the right setting, at the right time to optimise their care. 

The project will focus on the four elements of QIPP - Quality, Innovation, Productivity, Prevention – to transform local lipid pathways across Lambeth and Southwark boroughs to maximise outcomes for patients. 

Expected Outcomes
  • Standardised searches will be developed for GP IT systems to identify high-risk CVD patient cohorts
  • Number of patients identified at practice level within the agreed cohorts
  • Proportion of practices who have undertaken the relevant searches
  • Implementation of revised lipid protocols within participating practices
  • Improvements in lipid control within identified cohorts above, monitored at 6, 12 and 18 months
  • Reduction in absolute numbers of patients requiring lipid intervention when standardised searches are rerun at 6, 12 and 18 months
  • Increased confidence in lipid management across the primary care workforce
  • Clear pathway for referral implemented, including triage process in primary care
  • Increased uptake of second line therapies in line with NICE guidance
  • Integration of new technologies to improve efficiency and patient outcomes
  • Completed evaluation of project submitted for publication
  • Development of business case for sustainability and rollout across SEL CCG
  • Share business case across NHS systems

GB-REP-0720-00002 July 2020


 

Title

IDENTIFICATION AND MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA (FH) & HIGH-RISK CVD PATIENTS IN IRISH GENERAL PRACTICE.

Organisations Involved

The Irish College of General Practitioners (ICGP) and Amgen Ireland Ltd.

Joint Working Project Description

This partnership aims to test the test the feasibility of a general practice-based model of care to increase the detection of FH and high-risk CVD patients in Irish general practice leading to earlier identification and management of their CV risk.

Expected Outcomes

Key Outputs from the Joint Working Agreement include:
  • An increase the number of cases of FH identified through the recording of LDL and family history and a greater proportion of patients receiving management for their LDL-C in a sample of general practices in Ireland.
  • The partnership will generate aggregate data on the prevalence of high-risk CVD including FH in the Irish setting and identify individuals who may benefit from additional management.
  • The data from this partnership will support policy inclusion for a clinical pathway for the diagnosis and management of these patients in General Practice the Irish Healthcare setting.

IE-NPS-2000001 April 2020


 

Title

REDUCING CVD EVENTS BY OPTIMISING CHOLESTEROL MANAGEMENT FOR HIGH RISK PATIENTS IN THE NORTH WEST COAST REGION.


Organisations Involved

Amgen Limited and Innovation Agency NWC


Joint Working Project Description

The aim of the Project has been designed to support the delivery of the NHS CVD aspect of the Long-Term Plan.

The focus will be to improve cholesterol management, in Patients who are at a high risk of a CVD event or a further CVD event, to within parameters set by NICE guidelines with a focus on three areas:

  1. Support the clinical priority to reduce the number of CVD events.
  2. Ensure where appropriate, interventions are conducted in primary care by MDT teams within a primary care network (“PCN”) footprint.
  3. Use of population health analysis to identify cohorts of patients who are most in need of an intervention.
Expected Outcomes

Patients with persistently high cholesterol levels who are identified as high Risk for a CVD event or a further CVD event will be reviewed and managed optimally, as per NICE guidance CG181 AND CG71.

Audit tools, treatment and referral pathways as well as Primary Care upskilling to build on current management of Cholesterol will be reviewed with an expected reduction in CVD events as a direct result of optimising cholesterol levels in the practices involved in the project.  

GB-REP-1221-00019 December 2021




Title ESTABLISHMENT OF A NATIONAL FRACTURE LIAISON SERVICE IN IRELAND.
Organisations Involved Royal College of Surgeons of Ireland (RCSI), FLS Steering Committee Ireland & Amgen Ireland Ltd
Joint Working Project Description

This partnership with the RCSI aims to establish a Fracture Liaison Service (FLS) database in existing FLS centres.  The FLS Database will collect data that demonstrates to policy makers support for a national FLS in all 16 trauma centres will improve care standards for osteoporosis patients, lead to early identification and treatment initiation to prevent further debilitating fragility fractures.

Expected Outcomes

Key outputs from the Joint Working Agreement include:

  • Demonstrate clinical and cost effectiveness of FLS, by increased identification, investigation & initiation of treatment.
  • Deliver KPI driven quality care improvement
  • Enable prescription initiation & adherence data
  • Development of FLS patient pathway

UKIE-NPC-NPS-1219-080190 December 2019